阿黴素市場報告：按應用、分銷管道和地區分類（2026-2034 年）

2025年全球阿黴素市場規模達14億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到22億美元，2026年至2034年的複合年成長率為4.86%。

多柔比星（DOX）是一種用於癌症化療的學名藥。它以注射液或冷凍乾燥粉末的形式，透過周邊置入中央靜脈導管（PICC）或中央靜脈導管（CVC）靜脈注射給藥。靜脈注射後，DOX會被酵素迅速代謝，並在血漿中水解。此藥物用於治療多種癌症，包括乳癌、膀胱癌、卡波西氏肉瘤、淋巴瘤、威爾姆氏腫瘤非何傑金氏淋巴瘤和急性淋巴性白血病。

多柔比星市場趨勢：

癌症發生率的上升是推動全球多柔比星市場成長的主要因素。這導致多柔比星與其他化療藥物合併用於治療多種癌症的案例增加。此外，微創手術需求的成長以及無法接受大規模手術的老年患者數量的增加，也進一步強化了多柔比星作為癌症治療藥物的選擇。同時，世界各國政府正在推行各項舉措，支持臨床腫瘤學領域的技術進步，例如靜脈注射輸注療法和用於晶片生化分析的數位微流體技術。他們也在擴大癌症治療的宣傳教育。因此，對多柔比星的需求顯著成長。此外，研究人員也正在投入大量資金進行臨床試驗，以開發技術先進的多柔比星製劑。隨著旨在開展使用先進多柔比星製劑的臨床試驗的併購和合作不斷增加，預計未來幾年市場前景將十分樂觀。

市場區隔:

本報告分析了全球阿黴素市場各細分市場的關鍵趨勢，並對2026年至2034年全球、區域和國家特定市場進行了預測。市場按應用和分銷管道進行細分。

按用途細分：

• 乳癌
• 卵巢癌
• 多發性骨髓瘤
• 卡波西氏肉瘤
• 白血病
• 骨癌
• 子宮內膜癌
• 其他

按銷售管道細分：

• 醫院和零售藥局
• 網路商店
• 其他

按地區分類：

• 北美洲
• 我們
• 加拿大
• 亞太地區
• 中國
• 日本
• 印度
• 韓國
• 澳洲
• 印尼
• 其他
• 歐洲
• 德國
• 法國
• 英國
• 義大利
• 西班牙
• 俄羅斯
• 其他
• 拉丁美洲
• 巴西
• 墨西哥
• 其他
• 中東和非洲

競爭格局：

也調查了該行業的競爭格局，並分析了主要公司的概況，包括 Accord Healthcare Ltd.（Intas Pharmaceuticals Limited）、Baxter International Inc.、Cadila Pharmaceuticals、Cipla Inc.、Hikma Pharmaceuticals PLC、Meiji Holdings Co., Ltd.、Novartis AG 和 Pfizer Inc.。

本報告解答的主要問題

1. 多柔比星市場規模有多大？

2. 多柔比星市場的未來前景如何？

3. 推動阿黴素市場發展的主要因素是什麼？

4. 多柔比星在哪個地區擁有最大的市佔率？

5. 全球阿黴素市場的主要參與者有哪些？

目錄

第1章：序言

第2章：調查方法

• 調查目的
• 相關利益者
• 數據來源
  • 主要訊息
  • 次要訊息
• 市場估值
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第3章執行摘要

第4章：引言

第5章：全球阿黴素市場

• 市場概覽
• 市場表現
• 新冠疫情的影響
• 市場預測

第6章 市場區隔：依應用領域分類

• 乳癌
• 卵巢癌
• 多發性骨髓瘤
• 卡波西氏肉瘤
• 白血病
• 骨癌
• 子宮內膜癌
• 其他

第7章 市場區隔：依分銷通路分類

• 醫院和零售藥局
• 網路商店
• 其他

第8章 市場區隔：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
• 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

• 市場結構
• 大公司
• 主要公司簡介
  • Accord Healthcare Ltd.（Intas Pharmaceuticals Limited）
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Meiji Holdings Co. Ltd.
  • Novartis AG
  • Pfizer Inc.

The global doxorubicin market size reached USD 1.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.86% during 2026-2034.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Market Segmentation:

This report provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2026-2034. The report categorizes the market based on application and distribution channel.

Breakup by Application:

• Breast Cancer
• Ovarian Cancer
• Multiple Myeloma
• Kaposi Sarcoma
• Leukemia
• Bone Sarcoma
• Endometrial Cancer
• Others

Breakup by Distribution Channel:

• Hospital and Retail Pharmacies
• Online Stores
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report

1. How big is the doxorubicin market?

2. What is the future outlook of doxorubicin market?

3. What are the key factors driving the doxorubicin market?

4. Which region accounts for the largest doxorubicin market share?

5. Which are the leading companies in the global doxorubicin market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Doxorubicin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Breast Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Ovarian Cancer
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Multiple Myeloma
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Kaposi Sarcoma
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Leukemia
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Bone Sarcoma
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Endometrial Cancer
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Others
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital and Retail Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Online Stores
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Baxter International Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Cadila Pharmaceuticals
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Cipla Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Hikma Pharmaceuticals PLC
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 Meiji Holdings Co. Ltd.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Novartis AG
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Pfizer Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis

List of Figures

• Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
• Figure 2: Global: Doxorubicin Market: Sales Value (in Billion USD), 2020-2025
• Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion USD), 2026-2034
• Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2025
• Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2025
• Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2025
• Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 29: North America: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 31: United States: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 33: Canada: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 37: China: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 39: Japan: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 41: India: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 45: Australia: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 49: Others: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 51: Europe: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 53: Germany: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 55: France: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 59: Italy: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 61: Spain: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 63: Russia: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 65: Others: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 73: Others: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2025
• Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 78: Global: Doxorubicin Industry: SWOT Analysis
• Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
• Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2025 and 2034
• Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million USD), 2026-2034
• Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
• Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million USD), 2026-2034
• Table 5: Global: Doxorubicin Market: Competitive Structure
• Table 6: Global: Doxorubicin Market: Key Players